RxDoctor Payments Data

Brian Bearie

Emergency Medicine · San Bernardino, CANPI 1386754216

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Smith+Nephew accounts for 68.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $168 and has fallen 71.3% since, to $48 in 2024. Among emergency medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$426in general payments, 2019–2025

Across 19 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$291
  • Organogenesis Inc.$57
  • Hologic Sales And Service, LLC$38
  • Melinta Therapeutics, LLC$16
  • Convatec Inc.$14
  • Pfizer$10
$6,480,413in research payments, 2019–2025

Across 1,161 payments — averaging $5581.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$3.2M
  • Pfizer$882K
  • Lucira Health, Inc.$451K
  • Partner Therapeutics, Inc.$428K
  • Astrazeneca UK Limited$373K
  • GSK$303K
  • plus $852K from 12 others

What the payments were for

  • Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$426 in reported general payments places this provider in the 90th percentile of 6,006 emergency medicine providers in California.

See all emergency medicine providers in California

Medicare billing

Part B allowed, 2024
$130,580
Medicare patients
854
Services billed
2,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.11$11,846
Tramadol Hcl19$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$291$11,84611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,006 emergency medicine providers in California.

Other emergency medicine in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →